Clorox: Inflation Overhang and a Leadership Transition Cloud a Stabilizing Base
The Clorox Company's fourth-quarter earnings call arrived with a familiar but amplified set of pressures: consumer value-seeking, a competitive promotional environment, and now an inflation shock that management expects to be more than double its historical norm. Against that backdrop, CEO Linda Rendle also disclosed that a successor will be named after the board's search progresses, adding a leadership transition to an already busy turnaround narrative.
Inflation: More Than a Commodity Story
CFO Luc Bellet set the tone early, framing fiscal 2027 as an inflection point for costs. “we expect fiscal year '27 inflation to be above $200 million. So for perspective, it's about more than double our historical range, which has been in the $75 million to $100 million.” — Luc Bellet, Chief Financial Officer · 2026-08-03 The assumption of ~$90 Brent crude is only one pillar; logistics, freight, and broader supply-chain costs are adding to the pressure. This is a marked departure from the relatively muted inflation of the past two years, and it explains why the company's gross margin guidance for fiscal 2027 implies a temporary dip before recovering in the back half.
Gross margin stood at 43.2% in Q4, down 1.4 points year-over-year, and Luc's comments suggest another leg of pressure ahead as the $200M+ headwind hits the P&L.The company is not relying solely on pricing to offset the shock. Linda detailed a targeted approach, explaining that pricing is only one tool. “We are taking targeted or strategic pricing, and we've done that across the portfolio... the one category I called out that is more like it has been in the past is Glad given its exposure to commodities.” — Linda Rendle, Chair and Chief Executive Officer · 2026-08-03 That discipline is reflected in the company's broader strategic pricing narrative, which has shifted from broad-based increases to surgical adjustments that acknowledge a value-conscious consumer.
The previous quarter's call already foreshadowed this. Luc on the Q3 call noted, “We are assuming about $100 per barrel will be the midpoint of our estimate in Q4, which is about between $20 million and $25 million of headwinds or about 130 basis points of gross margin.” — Luc Bellet, CFO · 2026-04-30 The acceleration into fiscal 2027 is clearly the key theme investors are digesting.
Portfolio Momentum and the GOJO Wildcard
Amid the cost pressure, Clorox is leaning on portfolio actions to support growth. The GOJO acquisition, which closed earlier this year, is already showing signs of outperformance. Luc noted that GOJO was “accretive, not dilutive as we anticipated in the fourth quarter” — Luc Bellet, Chief Financial Officer · 2026-08-03 and expects it to be accretive to adjusted EPS in fiscal 2027. This is notable because the deal was originally expected to be neutral out of the gate, and it reinforces management's confidence in the health-and-hygiene platform.
On the core portfolio, Linda highlighted the strength in areas like Home Care, where the company has delivered eight consecutive quarters of share growth, and the turnaround in Hidden Valley, which benefited from World Cup activation. However, she also acknowledged that early innings of the Fresh Step/Fresh Step litter reinvention remain a work in progress, with product, packaging, and price action all being adjusted incrementally.
Meanwhile, the company is navigating a CEO transition. Linda, who has been transparent about her health challenges, said the board's search is progressing. “The Board has made good progress in the search... the search is progressing as expected against the time line the Board has laid out.” — Linda Rendle, Chair and Chief Executive Officer · 2026-08-03 She also expressed confidence that the current strategy and execution are setting the table for the next leader.
We're entering fiscal year 2027 from a stronger position than we started fiscal year 2026, and we expect that momentum to continue building as we move through the year.
Free Cash Flow and Balance Sheet
The quarter was also marked by a sharp swing in free cash flow, which turned negative at -$180M versus +$245M a year ago. This was driven by working capital timing and the GOJO-related cash outflows, but Luc reiterated that the full-year target of 11% to 13% of sales remains intact. The balance sheet remains a watchpoint; effective net cash stood at -$2.9B, a 25% year-over-year deterioration, as the company funds the GOJO deal and maintains its dividend. Liabilities-to-assets have crept up to 98.6%, underscoring the leverage taken on to fund the acquisition.
Given the macro backdrop and the internal transition, the board's decision to modestly increase the dividend again—now implying a payout ratio near 85% of net earnings—has drawn questions from analysts. Luc defended the policy, calling it “transitory” as gross margin rebuilds, but it remains a point of investor debate.
Despite all the moving pieces, the stock has been remarkably stable, trading flat over the past 90 days, suggesting the market is already pricing in a slower recovery. The key tests will be whether the company can execute on its back-half gross margin recovery, win back share in Litter, and successfully shepherd the CEO transition without losing momentum.